Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States
In this observational, single-cohort study, at 6-month follow-up, patients with T2D initiating tirzepatide showed HbA1c and weight reductions; more pronounced HbA1c reductions occurred in GLP-1 RA naïve patients or those with baseline HbA1c ≥7%, while more weight loss was observed among GLP-1 RA naïve patients or those with baseline HbA1c <7%.
Authors
- Reema Mody (ORCID: https://orcid.org/0000-0002-3442-1714)
- Gally Reznor
- Brian D. Benneyworth (ORCID: https://orcid.org/0000-0002-4692-5303)
- Grace Stockbower
- Michael Grabner (ORCID: https://orcid.org/0000-0002-6521-1007)
- Chia‐Chen Teng
- Karishma Desai (ORCID: https://orcid.org/0000-0001-6108-4154)
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1111/dom.16372
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Eli Lilly and Company